<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35334233</PMID><DateCompleted><Year>2022</Year><Month>04</Month><Day>19</Day></DateCompleted><DateRevised><Year>2023</Year><Month>05</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1474-4465</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>5</Issue><PubDate><Year>2022</Year><Month>May</Month></PubDate></JournalIssue><Title>The Lancet. Neurology</Title><ISOAbbreviation>Lancet Neurol</ISOAbbreviation></Journal><ArticleTitle>Recent advances in the diagnosis and prognosis of amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>480</StartPage><EndPage>493</EndPage><MedlinePgn>480-493</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/S1474-4422(21)00465-8</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1474-4422(21)00465-8</ELocationID><Abstract><AbstractText>The diagnosis of amyotrophic lateral sclerosis can be challenging due to its heterogeneity in clinical presentation and overlap with other neurological disorders. Diagnosis early in the disease course can improve outcomes as timely interventions can slow disease progression. An evolving awareness of disease genotypes and phenotypes and new diagnostic criteria, such as the recent Gold Coast criteria, could expedite diagnosis. Improved prognosis, such as that achieved with the survival model from the European Network for the Cure of ALS, could inform the patient and their family about disease course and improve end-of-life planning. Novel staging and scoring systems can help monitor disease progression and might potentially serve as clinical trial outcomes. Lastly, new tools, such as fluid biomarkers, imaging modalities, and neuromuscular electrophysiological measurements, might increase diagnostic and prognostic accuracy.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Goutman</LastName><ForeName>Stephen A</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Michigan, Ann Arbor, MI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hardiman</LastName><ForeName>Orla</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Academic Unit of Neurology, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Al-Chalabi</LastName><ForeName>Ammar</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Basic and Clinical Neuroscience, Maurice Wohl Clinical Neuroscience Institute, and Department of Neurology, King's College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chi&#xf3;</LastName><ForeName>Adriano</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Rita Levi Montalcini Department of Neurosciences, University of Turin, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Savelieff</LastName><ForeName>Masha G</ForeName><Initials>MG</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Michigan, Ann Arbor, MI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kiernan</LastName><ForeName>Matthew C</ForeName><Initials>MC</Initials><AffiliationInfo><Affiliation>Brain and Mind Centre, University of Sydney, Sydney, NSW, Australia; Department of Neurology, Royal Prince Alfred Hospital, Sydney, NSW, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Feldman</LastName><ForeName>Eva L</ForeName><Initials>EL</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Michigan, Ann Arbor, MI, USA. Electronic address: efeldman@umich.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 TS000327</GrantID><Acronym>TS</Acronym><Agency>ATSDR CDC HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 ES027221</GrantID><Acronym>ES</Acronym><Agency>NIEHS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MR/L501529/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>ALCHALABI-TALBOT/APR14/926-794</GrantID><Acronym>MNDA_</Acronym><Agency>Motor Neurone Disease Association</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>R01 ES030049</GrantID><Acronym>ES</Acronym><Agency>NIEHS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>ALCHALABI-DOBSON/APR14/829-791</GrantID><Acronym>MNDA_</Acronym><Agency>Motor Neurone Disease Association</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>R01 NS120926</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS127188</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MR/R024804/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>R01 TS000289</GrantID><Acronym>TS</Acronym><Agency>ATSDR CDC HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>03</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lancet Neurol</MedlineTA><NlmUniqueID>101139309</NlmUniqueID><ISSNLinking>1474-4422</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Lancet Neurol. 2022 May;21(5):400-401</RefSource><PMID Version="1">35334235</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004576" MajorTopicYN="N">Electromyography</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>Declaration of interests SAG declares consulting fees from Biogen and ITF Pharma, a patent &#x201c;Methods for treating amyotrophic lateral sclerosis&#x201d;, and participation on a Data Safety Monitoring Board for Watermark. OH declares consulting fees from Novartis, Cytokinetics, Denali Pharma, Stitching Foundation, and La Caixa; payment or honoraria from Biogen; participation on a Data Safety Monitoring Board for Accelsiors and steering committee for Cytokinetics; and is Editor-in-Chief for the journal Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. AA-C declares consulting fees from Mitsubishi Tanabe Pharma, Biogen Idec, Cytokinetics, Wave Pharmaceuticals, Apellis, Amylyx, Novartis, and Eli Lilly. AC declares grants from Biogen to his institution, payments or honoraria from Biogen and Amylyx, and participation on a Data Safety Monitoring Board for Ely Lilly and ABScience and advisory board for Mitsubishi Tanabe, Roche, Denali Pharma, Cytokinetics, Biogen, and Amylyx. MCK has an honorary role as President of the Brain Foundation and as Editor-in-Chief of the Journal of Neurology, Neurosurgery and Psychiatry. ELF declares a patent &#x201c;Methods for treating amyotrophic lateral sclerosis&#x201d;. MGS declares no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>8</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>11</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>12</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>3</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>4</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>3</Month><Day>25</Day><Hour>20</Hour><Minute>7</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35334233</ArticleId><ArticleId IdType="mid">NIHMS1833654</ArticleId><ArticleId IdType="pmc">PMC9513753</ArticleId><ArticleId IdType="doi">10.1016/S1474-4422(21)00465-8</ArticleId><ArticleId IdType="pii">S1474-4422(21)00465-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Goutman SA. Diagnosis and Clinical Management of Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders. Continuum (Minneap Minn). Oct 2017;23(5, Peripheral Nerve and Motor Neuron Disorders):1332&#x2013;1359. doi:10.1212/con.0000000000000535</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/con.0000000000000535</ArticleId><ArticleId IdType="pubmed">28968365</ArticleId></ArticleIdList></Reference><Reference><Citation>Richards D, Morren JA, Pioro EP. Time to diagnosis and factors affecting diagnostic delay in amyotrophic lateral sclerosis. J Neurol Sci. Oct 15 2020;417:117054. doi:10.1016/j.jns.2020.117054</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2020.117054</ArticleId><ArticleId IdType="pubmed">32763509</ArticleId></ArticleIdList></Reference><Reference><Citation>Galvin M, Ryan P, Maguire S, et al. The path to specialist multidisciplinary care in amyotrophic lateral sclerosis: A population- based study of consultations, interventions and costs. PLoS One. 2017;12(6):e0179796. doi:10.1371/journal.pone.0179796</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0179796</ArticleId><ArticleId IdType="pmc">PMC5480998</ArticleId><ArticleId IdType="pubmed">28640860</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu L, Liu T, Liu L, et al. Global variation in prevalence and incidence of amyotrophic lateral sclerosis: a systematic review and meta-analysis. J Neurol. Apr 2020;267(4):944&#x2013;953. doi:10.1007/s00415-019-09652-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-019-09652-y</ArticleId><ArticleId IdType="pubmed">31797084</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi&#xf2; A, Moglia C, Canosa A, et al. ALS phenotype is influenced by age, sex, and genetics: A population-based study. Neurology. Feb 25 2020;94(8):e802&#x2013;e810. doi:10.1212/wnl.0000000000008869</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/wnl.0000000000008869</ArticleId><ArticleId IdType="pubmed">31907290</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryan M, Heverin M, McLaughlin RL, Hardiman O. Lifetime Risk and Heritability of Amyotrophic Lateral Sclerosis. JAMA Neurol. Nov 1 2019;76(11):1367&#x2013;1374. doi:10.1001/jamaneurol.2019.2044</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2019.2044</ArticleId><ArticleId IdType="pmc">PMC6646974</ArticleId><ArticleId IdType="pubmed">31329211</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy NA, Arthur KC, Tienari PJ, Houlden H, Chio A, Traynor BJ. Age-related penetrance of the C9orf72 repeat expansion. Sci Rep. May 18 2017;7(1):2116. doi:10.1038/s41598-017-02364-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-02364-1</ArticleId><ArticleId IdType="pmc">PMC5437033</ArticleId><ArticleId IdType="pubmed">28522837</ArticleId></ArticleIdList></Reference><Reference><Citation>Swinnen B, Robberecht W. The phenotypic variability of amyotrophic lateral sclerosis. Nature reviews Neurology. Nov 2014;10(11):661&#x2013;70. doi:10.1038/nrneurol.2014.184</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2014.184</ArticleId><ArticleId IdType="pubmed">25311585</ArticleId></ArticleIdList></Reference><Reference><Citation>Talman P, Duong T, Vucic S, et al. Identification and outcomes of clinical phenotypes in amyotrophic lateral sclerosis/motor neuron disease: Australian National Motor Neuron Disease observational cohort. BMJ Open. Sep 30 2016;6(9):e012054. doi:10.1136/bmjopen-2016-012054</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2016-012054</ArticleId><ArticleId IdType="pmc">PMC5051496</ArticleId><ArticleId IdType="pubmed">27694488</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi&#xf2; A, Calvo A, Moglia C, Mazzini L, Mora G. Phenotypic heterogeneity of amyotrophic lateral sclerosis: a population based study. J Neurol Neurosurg Psychiatry. Jul 2011;82(7):740&#x2013;6. doi:10.1136/jnnp.2010.235952</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.2010.235952</ArticleId><ArticleId IdType="pubmed">21402743</ArticleId></ArticleIdList></Reference><Reference><Citation>Moglia C, Calvo A, Brunetti M, Chi&#xf2; A, Grassano M. Broadening the clinical spectrum of FUS mutations: a case with monomelic amyotrophy with a late progression to amyotrophic lateral sclerosis. Neurol Sci. 2021:1207&#x2013;1209. vol. 3.</Citation><ArticleIdList><ArticleId IdType="pubmed">33001405</ArticleId></ArticleIdList></Reference><Reference><Citation>Roche JC, Rojas-Garcia R, Scott KM, et al. A proposed staging system for amyotrophic lateral sclerosis. Brain : a journal of neurology. Mar 2012;135(Pt 3):847&#x2013;52. doi:10.1093/brain/awr351</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awr351</ArticleId><ArticleId IdType="pmc">PMC3286327</ArticleId><ArticleId IdType="pubmed">22271664</ArticleId></ArticleIdList></Reference><Reference><Citation>Westeneng HJ, Debray TPA, Visser AE, et al. Prognosis for patients with amyotrophic lateral sclerosis: development and validation of a personalised prediction model. The Lancet Neurology. May 2018;17(5):423&#x2013;433. doi:10.1016/S1474-4422(18)30089-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(18)30089-9</ArticleId><ArticleId IdType="pubmed">29598923</ArticleId></ArticleIdList></Reference><Reference><Citation>Rabinovici GD, Stephens ML, Possin KL. Executive dysfunction. Continuum (Minneap Minn). Jun 2015;21(3 Behavioral Neurology and Neuropsychiatry):646&#x2013;59. doi:10.1212/01.CON.0000466658.05156.54</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.CON.0000466658.05156.54</ArticleId><ArticleId IdType="pmc">PMC4455841</ArticleId><ArticleId IdType="pubmed">26039846</ArticleId></ArticleIdList></Reference><Reference><Citation>Strong MJ, Abrahams S, Goldstein LH, et al. Amyotrophic lateral sclerosis - frontotemporal spectrum disorder (ALS-FTSD): Revised diagnostic criteria. Amyotroph Lateral Scler Frontotemporal Degener. May 2017;18(3&#x2013;4):153&#x2013;174. doi:10.1080/21678421.2016.1267768</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2016.1267768</ArticleId><ArticleId IdType="pmc">PMC7409990</ArticleId><ArticleId IdType="pubmed">28054827</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinto-Grau M, Donohoe B, O&#x2019;Connor S, et al. Patterns of Language Impairment in Early ALS. Neurology: Clinical Practice. 2020:10.1212/CPJ.0000000000001006. doi:10.1212/cpj.0000000000001006</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/cpj.0000000000001006</ArticleId><ArticleId IdType="pmc">PMC8610537</ArticleId><ArticleId IdType="pubmed">34840877</ArticleId></ArticleIdList></Reference><Reference><Citation>Crockford C, Newton J, Lonergan K, et al. ALS-specific cognitive and behavior changes associated with advancing disease stage in ALS. Neurology. Oct 9 2018;91(15):e1370&#x2013;e1380. doi:10.1212/WNL.0000000000006317</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000006317</ArticleId><ArticleId IdType="pmc">PMC6177274</ArticleId><ArticleId IdType="pubmed">30209236</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicholson K, Murphy A, McDonnell E, et al. Improving symptom management for people with amyotrophic lateral sclerosis. Muscle Nerve. Jan 2018;57(1):20&#x2013;24. doi:10.1002/mus.25712</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.25712</ArticleId><ArticleId IdType="pubmed">28561886</ArticleId></ArticleIdList></Reference><Reference><Citation>Elamin M, Bede P, Byrne S, et al. Cognitive changes predict functional decline in ALS: a population-based longitudinal study. Neurology. Apr 23 2013;80(17):1590&#x2013;7. doi:10.1212/WNL.0b013e31828f18ac</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e31828f18ac</ArticleId><ArticleId IdType="pubmed">23553481</ArticleId></ArticleIdList></Reference><Reference><Citation>Caga J, Hsieh S, Highton-Williamson E, et al. The burden of apathy for caregivers of patients with amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. Nov 2018;19(7&#x2013;8):599&#x2013;605. doi:10.1080/21678421.2018.1497659</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2018.1497659</ArticleId><ArticleId IdType="pubmed">30369270</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen DR, Siddique T, Patterson D, et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature Mar 4 1993;362(6415):59&#x2013;62. doi:10.1038/362059a0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/362059a0</ArticleId><ArticleId IdType="pubmed">8446170</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton AE, Majounie E, Waite A, et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron Oct 20 2011;72(2):257&#x2013;68. doi:10.1016/j.neuron.2011.09.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2011.09.010</ArticleId><ArticleId IdType="pmc">PMC3200438</ArticleId><ArticleId IdType="pubmed">21944779</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiernan MC, Vucic S, Talbot K, et al. Improving clinical trial outcomes in amyotrophic lateral sclerosis. Nat Rev Neurol. Feb 2021;17(2):104&#x2013;118. doi:10.1038/s41582-020-00434-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41582-020-00434-z</ArticleId><ArticleId IdType="pmc">PMC7747476</ArticleId><ArticleId IdType="pubmed">33340024</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks BR, Miller RG, Swash M, Munsat TL. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. Dec 2000;1(5):293&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">11464847</ArticleId></ArticleIdList></Reference><Reference><Citation>Costa J, Swash M, de Carvalho M. Awaji criteria for the diagnosis of amyotrophic lateral sclerosis:a systematic review. Arch Neurol. Nov 2012;69(11):1410&#x2013;6. doi:10.1001/archneurol.2012.254</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneurol.2012.254</ArticleId><ArticleId IdType="pubmed">22892641</ArticleId></ArticleIdList></Reference><Reference><Citation>van den Berg LH, Sorenson E, Gronseth G, et al. Revised Airlie House consensus guidelines for design and implementation of ALS clinical trials. Neurology. Apr 2 2019;92(14):e1610&#x2013;e1623. doi:10.1212/WNL.0000000000007242</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000007242</ArticleId><ArticleId IdType="pmc">PMC6448453</ArticleId><ArticleId IdType="pubmed">30850440</ArticleId></ArticleIdList></Reference><Reference><Citation>Vucic S, Ferguson TA, Cummings C, et al. Gold Coast diagnostic criteria: Implications for ALS diagnosis and clinical trial enrollment. Muscle Nerve. Aug 11 2021;doi:10.1002/mus.27392</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.27392</ArticleId><ArticleId IdType="pubmed">34378224</ArticleId></ArticleIdList></Reference><Reference><Citation>Shefner JM, Al-Chalabi A, Baker MR, et al. A proposal for new diagnostic criteria for ALS. Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology. Aug 2020;131(8):1975&#x2013;1978. doi:10.1016/j.clinph.2020.04.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinph.2020.04.005</ArticleId><ArticleId IdType="pubmed">32387049</ArticleId></ArticleIdList></Reference><Reference><Citation>Hannaford A, Pavey N, van den Bos M, et al. Diagnostic Utility of Gold Coast Criteria in Amyotrophic Lateral Sclerosis. Ann Neurol. May 2021;89(5):979&#x2013;986. doi:10.1002/ana.26045</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.26045</ArticleId><ArticleId IdType="pubmed">33565111</ArticleId></ArticleIdList></Reference><Reference><Citation>Pugdahl K, Camdessanch&#xe9; JP, Cengiz B, et al. Gold Coast diagnostic criteria increase sensitivity in amyotrophic lateral sclerosis. Clin Neurophysiol. Sep 8 2021;doi:10.1016/j.clinph.2021.08.014</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinph.2021.08.014</ArticleId><ArticleId IdType="pubmed">34544646</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen D, Yang X, Wang Y, et al. The Gold Coast criteria increases the diagnostic sensitivity for amyotrophic lateral sclerosis in a Chinese population. Transl Neurodegener. Aug 9 2021;10(1):28. doi:10.1186/s40035-021-00253-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40035-021-00253-2</ArticleId><ArticleId IdType="pmc">PMC8351337</ArticleId><ArticleId IdType="pubmed">34372918</ArticleId></ArticleIdList></Reference><Reference><Citation>Estevez-Fraga C, Magrinelli F, Hensman Moss D, et al. Expanding the Spectrum of Movement Disorders Associated With C9orf72 Hexanucleotide Expansions. Neurol Genet. Apr 2021;7(2):e575. doi:10.1212/NXG.0000000000000575</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/NXG.0000000000000575</ArticleId><ArticleId IdType="pmc">PMC8105892</ArticleId><ArticleId IdType="pubmed">33977144</ArticleId></ArticleIdList></Reference><Reference><Citation>Hensman Moss DJ, Poulter M, Beck J, et al. C9orf72 expansions are the most common genetic cause of Huntington disease phenocopies. Neurology. Jan 28 2014;82(4):292&#x2013;9. doi:10.1212/WNL.0000000000000061</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000000061</ArticleId><ArticleId IdType="pmc">PMC3929197</ArticleId><ArticleId IdType="pubmed">24363131</ArticleId></ArticleIdList></Reference><Reference><Citation>Dewan R, Chia R, Ding J, et al. Pathogenic Huntingtin Repeat Expansions in Patients with Frontotemporal Dementia and Amyotrophic Lateral Sclerosis. Neuron. Feb 3 2021;109(3):448&#x2013;460 e4. doi:10.1016/j.neuron.2020.11.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2020.11.005</ArticleId><ArticleId IdType="pmc">PMC7864894</ArticleId><ArticleId IdType="pubmed">33242422</ArticleId></ArticleIdList></Reference><Reference><Citation>Devenney EM, Ahmed RM, Halliday G, Piguet O, Kiernan MC, Hodges JR. Psychiatric disorders in C9orf72 kindreds: Study of 1,414 family members. Neurology. Oct 16 2018;91(16):e1498&#x2013;e1507. doi:10.1212/WNL.0000000000006344</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000006344</ArticleId><ArticleId IdType="pubmed">30258023</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang CP, Li X, Wu Y, et al. Comprehensive integrative analyses identify GLT8D1 and CSNK2B as schizophrenia risk genes. Nat Commun. Feb 26 2018;9(1):838. doi:10.1038/s41467-018-03247-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-018-03247-3</ArticleId><ArticleId IdType="pmc">PMC5826945</ArticleId><ArticleId IdType="pubmed">29483533</ArticleId></ArticleIdList></Reference><Reference><Citation>McLaughlin RL, Schijven D, van Rheenen W, et al. Genetic correlation between amyotrophic lateral sclerosis and schizophrenia. Nature Communications. 2017/03/21 2017;8(1):14774. doi:10.1038/ncomms14774</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms14774</ArticleId><ArticleId IdType="pmc">PMC5364411</ArticleId><ArticleId IdType="pubmed">28322246</ArticleId></ArticleIdList></Reference><Reference><Citation>Rooney J, Burke T, Vajda A, Heverin M, Hardiman O. What does the ALSFRS-R really measure? A longitudinal and survival analysis of functional dimension subscores in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. May 2017;88(5):381&#x2013;385. doi:10.1136/jnnp-2016-314661</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2016-314661</ArticleId><ArticleId IdType="pubmed">27888187</ArticleId></ArticleIdList></Reference><Reference><Citation>Cedarbaum JM, Stambler N, Malta E, et al. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III). Journal of the neurological sciences. Oct 31 1999;169(1&#x2013;2):13&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">10540002</ArticleId></ArticleIdList></Reference><Reference><Citation>van Eijk RPA, de Jongh AD, Nikolakopoulos S, et al. An old friend who has overstayed their welcome: the ALSFRS-R total score as primary endpoint for ALS clinical trials. Amyotroph Lateral Scler Frontotemporal Degener. May 2021;22(3&#x2013;4):300&#x2013;307. doi:10.1080/21678421.2021.1879865</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2021.1879865</ArticleId><ArticleId IdType="pubmed">33527843</ArticleId></ArticleIdList></Reference><Reference><Citation>Bedlack RS, Vaughan T, Wicks P, et al. How common are ALS plateaus and reversals? Neurology. Mar 1 2016;86(9):808&#x2013;12. doi:10.1212/wnl.0000000000002251</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/wnl.0000000000002251</ArticleId><ArticleId IdType="pmc">PMC4793781</ArticleId><ArticleId IdType="pubmed">26658909</ArticleId></ArticleIdList></Reference><Reference><Citation>Pirola A, De Mattia E, Lizio A, et al. The prognostic value of spirometric tests in Amyotrophic Lateral Sclerosis patients. Clin Neurol Neurosurg. Sep 2019;184:105456. doi:10.1016/j.clineuro.2019.105456</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clineuro.2019.105456</ArticleId><ArticleId IdType="pubmed">31382080</ArticleId></ArticleIdList></Reference><Reference><Citation>Fournier CN, Bedlack R, Quinn C, et al. Development and Validation of the Rasch-Built Overall Amyotrophic Lateral Sclerosis Disability Scale (ROADS). JAMA neurology. Dec 30 2019;doi:10.1001/jamaneurol.2019.4490</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2019.4490</ArticleId><ArticleId IdType="pmc">PMC6990811</ArticleId><ArticleId IdType="pubmed">31886839</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi&#xf2; A, Hammond ER, Mora G, Bonito V, Filippini G. Development and evaluation of a clinical staging system for amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry Jan 015;86(1):38&#x2013;44. doi:10.1136/jnnp-2013-306589</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2013-306589</ArticleId><ArticleId IdType="pubmed">24336810</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang T, Al Khleifat A, Stahl DR, et al. Comparison of the King&#x2019;s and MiToS staging systems for ALS. Amyotroph Lateral Scler Frontotemporal Degener. May 2017;18(3&#x2013;4):227&#x2013;232. doi:10.1080/21678421.2016.1265565</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2016.1265565</ArticleId><ArticleId IdType="pmc">PMC5425622</ArticleId><ArticleId IdType="pubmed">28054828</ArticleId></ArticleIdList></Reference><Reference><Citation>Luna J, Couratier P, Lahmadi S, et al. Comparison of the ability of the King&#x2019;s and MiToS staging systems to predict disease progression and survival in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. Apr 8 2021:1&#x2013;9. doi:10.1080/21678421.2021.1903506</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2021.1903506</ArticleId><ArticleId IdType="pubmed">33829938</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Chalabi A, Chi&#xf2; A, Merrill C, et al. Clinical staging in amyotrophic lateral sclerosis: analysis of Edaravone Study 19. J Neurol Neurosurg Psychiatry. Feb 2021;92(2):165&#x2013;171. doi:10.1136/jnnp-2020-323271</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2020-323271</ArticleId><ArticleId IdType="pmc">PMC7841496</ArticleId><ArticleId IdType="pubmed">33109706</ArticleId></ArticleIdList></Reference><Reference><Citation>Westeneng HJ, Al-Chalabi A, Hardiman O, Debray TP, van den Berg LH. The life expectancy of Stephen Hawking, according to the ENCALS model. Lancet Neurol. Aug 2018;17(8):662&#x2013;663. doi:10.1016/s1474-4422(18)30241-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s1474-4422(18)30241-2</ArticleId><ArticleId IdType="pubmed">30033055</ArticleId></ArticleIdList></Reference><Reference><Citation>Lenglet T, Camdessanch&#xe9; JP. Amyotrophic lateral sclerosis or not: Keys for the diagnosis. Rev Neurol (Paris). May 2017;173(5):280&#x2013;287. doi:10.1016/j.neurol.2017.04.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurol.2017.04.003</ArticleId><ArticleId IdType="pubmed">28461025</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang F, Zhu Y, Hsiao-Nakamoto J, et al. Longitudinal biomarkers in amyotrophic lateral sclerosis. Ann Clin Transl Neurol. Jul 2020;7(7):1103&#x2013;1116. doi:10.1002/acn3.51078</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.51078</ArticleId><ArticleId IdType="pmc">PMC7359115</ArticleId><ArticleId IdType="pubmed">32515902</ArticleId></ArticleIdList></Reference><Reference><Citation>Benatar M, Wuu J, Andersen PM, Lombardi V, Malaspina A. Neurofilament light: A candidate biomarker of presymptomatic amyotrophic lateral sclerosis and phenoconversion. Ann Neurol. Jul 2018;84(1):130&#x2013;139. doi:10.1002/ana.25276</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.25276</ArticleId><ArticleId IdType="pubmed">30014505</ArticleId></ArticleIdList></Reference><Reference><Citation>Poesen K, De Schaepdryver M, Stubendorff B, et al. Neurofilament markers for ALS correlate with extent of upper and lower motor neuron disease. Neurology. Jun 13 2017;88(24):2302&#x2013;2309. doi:10.1212/WNL.0000000000004029</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000004029</ArticleId><ArticleId IdType="pubmed">28500227</ArticleId></ArticleIdList></Reference><Reference><Citation>Benatar M, Zhang L, Wang L, et al. Validation of serum neurofilaments as prognostic and potential pharmacodynamic biomarkers for ALS. Neurology. Jul 7 2020;95(1):e59&#x2013;e69. doi:10.1212/wnl.0000000000009559</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/wnl.0000000000009559</ArticleId><ArticleId IdType="pmc">PMC7371380</ArticleId><ArticleId IdType="pubmed">32385188</ArticleId></ArticleIdList></Reference><Reference><Citation>Gafson AR, Barth&#xe9;lemy NR, Bomont P, et al. Neurofilaments: neurobiological foundations for biomarker applications. Brain. Jul 1 2020;143(7):1975&#x2013;1998. doi:10.1093/brain/awaa098</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awaa098</ArticleId><ArticleId IdType="pmc">PMC7363489</ArticleId><ArticleId IdType="pubmed">32408345</ArticleId></ArticleIdList></Reference><Reference><Citation>Halbgebauer S, Steinacker P, Verde F, et al. Comparison of CSF and serum neurofilament light and heavy chain as differential diagnostic biomarkers for ALS. J Neurol Neurosurg Psychiatry. Aug 20 2021;doi:10.1136/jnnp-2021-327129</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2021-327129</ArticleId><ArticleId IdType="pubmed">34417339</ArticleId></ArticleIdList></Reference><Reference><Citation>Kassubek J, Pagani M. Imaging in amyotrophic lateral sclerosis: MRI and PET. Curr Opin Neurol. Oct 2019;32(5):740&#x2013;746. doi:10.1097/wco.0000000000000728</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/wco.0000000000000728</ArticleId><ArticleId IdType="pubmed">31335337</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalra S, M&#xfc;ller HP, Ishaque A, et al. A prospective harmonized multicenter DTI study of cerebral white matter degeneration in ALS. Neurology. Aug 25 2020;95(8):e943&#x2013;e952. doi:10.1212/wnl.0000000000010235</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/wnl.0000000000010235</ArticleId><ArticleId IdType="pmc">PMC7668555</ArticleId><ArticleId IdType="pubmed">32646955</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferraro PM, Agosta F, Riva N, et al. Multimodal structural MRI in the diagnosis of motor neuron diseases. Neuroimage Clin. 2017;16:240&#x2013;247. doi:10.1016/j.nicl.2017.08.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nicl.2017.08.002</ArticleId><ArticleId IdType="pmc">PMC5545829</ArticleId><ArticleId IdType="pubmed">28794983</ArticleId></ArticleIdList></Reference><Reference><Citation>Agosta F, Spinelli EG, Riva N, et al. Survival prediction models in motor neuron disease. Eur J Neurol. Sep 2019;26(9):1143&#x2013;1152. doi:10.1111/ene.13957</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.13957</ArticleId><ArticleId IdType="pubmed">30920076</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuster C, Hardiman O, Bede P. Survival prediction in Amyotrophic lateral sclerosis based on MRI measures and clinical characteristics. BMC Neurol. Apr 17 2017;17(1):73. doi:10.1186/s12883-017-0854-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12883-017-0854-x</ArticleId><ArticleId IdType="pmc">PMC5393027</ArticleId><ArticleId IdType="pubmed">28412941</ArticleId></ArticleIdList></Reference><Reference><Citation>Querin G, Bede P, El Mendili MM, et al. Presymptomatic spinal cord pathology in c9orf72 mutation carriers: A longitudinal neuroimaging study. Ann Neurol. Aug 2019;86(2):158&#x2013;167. doi:10.1002/ana.25520</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.25520</ArticleId><ArticleId IdType="pubmed">31177556</ArticleId></ArticleIdList></Reference><Reference><Citation>Querin G, El Mendili MM, Lenglet T, et al. Spinal cord multi-parametric magnetic resonance imaging for survival prediction in amyotrophic lateral sclerosis. Eur J Neurol. Aug 2017;24(8):1040&#x2013;1046. doi:10.1111/ene.13329</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.13329</ArticleId><ArticleId IdType="pubmed">28586096</ArticleId></ArticleIdList></Reference><Reference><Citation>El Mendili MM, Querin G, Bede P, Pradat PF. Spinal Cord Imaging in Amyotrophic Lateral Sclerosis: Historical Concepts-Novel Techniques. Front Neurol. 2019;10:350. doi:10.3389/fneur.2019.00350</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2019.00350</ArticleId><ArticleId IdType="pmc">PMC6474186</ArticleId><ArticleId IdType="pubmed">31031688</ArticleId></ArticleIdList></Reference><Reference><Citation>Fabes J, Matthews L, Filippini N, Talbot K, Jenkinson M, Turner MR. Quantitative FLAIR MRI in Amyotrophic Lateral Sclerosis. Acad Radiol. Oct 2017;24(10):1187&#x2013;1194. doi:10.1016/j.acra.2017.04.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.acra.2017.04.008</ArticleId><ArticleId IdType="pmc">PMC5605225</ArticleId><ArticleId IdType="pubmed">28572001</ArticleId></ArticleIdList></Reference><Reference><Citation>Roeben B, Wilke C, Bender B, Ziemann U, Synofzik M. The motor band sign in ALS: presentations and frequencies in a consecutive series of ALS patients. J Neurol Sci. Nov 15 2019;406:116440. doi:10.1016/j.jns.2019.116440</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2019.116440</ArticleId><ArticleId IdType="pubmed">31521959</ArticleId></ArticleIdList></Reference><Reference><Citation>Menke RAL, Proudfoot M, Talbot K, Turner MR. The two-year progression of structural and functional cerebral MRI in amyotrophic lateral sclerosis. Neuroimage Clin. 2018;17:953&#x2013;961. doi:10.1016/j.nicl.2017.12.025</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nicl.2017.12.025</ArticleId><ArticleId IdType="pmc">PMC5752097</ArticleId><ArticleId IdType="pubmed">29321969</ArticleId></ArticleIdList></Reference><Reference><Citation>Meier JM, van der Burgh HK, Nitert AD, et al. Connectome-Based Propagation Model in Amyotrophic Lateral Sclerosis. Ann Neurol. May 2020;87(5):725&#x2013;738. doi:10.1002/ana.25706</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.25706</ArticleId><ArticleId IdType="pmc">PMC7186838</ArticleId><ArticleId IdType="pubmed">32072667</ArticleId></ArticleIdList></Reference><Reference><Citation>Welton T, Maller JJ, Lebel RM, Tan ET, Rowe DB, Grieve SM. Diffusion kurtosis and quantitative susceptibility mapping MRI are sensitive to structural abnormalities in amyotrophic lateral sclerosis. Neuroimage Clin. 2019;24:101953. doi:10.1016/j.nicl.2019.101953</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nicl.2019.101953</ArticleId><ArticleId IdType="pmc">PMC6664242</ArticleId><ArticleId IdType="pubmed">31357149</ArticleId></ArticleIdList></Reference><Reference><Citation>Bede P, Hardiman O. Longitudinal structural changes in ALS: a three time-point imaging study of white and gray matter degeneration. Amyotroph Lateral Scler Frontotemporal Degener. May 2018;19(3&#x2013;4):232&#x2013;241. doi:10.1080/21678421.2017.1407795</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2017.1407795</ArticleId><ArticleId IdType="pubmed">29214883</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuster C, Hardiman O, Bede P. Development of an Automated MRI-Based Diagnostic Protocol for Amyotrophic Lateral Sclerosis Using Disease-Specific Pathognomonic Features: A Quantitative Disease-State Classification Study. PLoS One. 2016;11(12):e0167331. doi:10.1371/journal.pone.0167331</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0167331</ArticleId><ArticleId IdType="pmc">PMC5132189</ArticleId><ArticleId IdType="pubmed">27907080</ArticleId></ArticleIdList></Reference><Reference><Citation>Basaia S, Agosta F, Cividini C, et al. Structural and functional brain connectome in motor neuron diseases: A multicenter MRI study. Neurology. Nov 3 2020;95(18):e2552&#x2013;e2564. doi:10.1212/WNL.0000000000010731</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000010731</ArticleId><ArticleId IdType="pmc">PMC7682834</ArticleId><ArticleId IdType="pubmed">32913015</ArticleId></ArticleIdList></Reference><Reference><Citation>Acosta-Cabronero J, Machts J, Schreiber S, et al. Quantitative Susceptibility MRI to Detect Brain Iron in Amyotrophic Lateral Sclerosis. Radiology. Oct 2018;289(1):195&#x2013;203. doi:10.1148/radiol.2018180112</Citation><ArticleIdList><ArticleId IdType="doi">10.1148/radiol.2018180112</ArticleId><ArticleId IdType="pmc">PMC6166868</ArticleId><ArticleId IdType="pubmed">30040038</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#x2019;Hulst L, Van Weehaeghe D, Chio A, et al. Multicenter validation of [(18)F]-FDG PET and support-vector machine discriminant analysis in automatically classifying patients with amyotrophic lateral sclerosis versus controls. Amyotroph Lateral Scler Frontotemporal Degener. Nov 2018;19(7&#x2013;8):570&#x2013;577. doi:10.1080/21678421.2018.1476548</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2018.1476548</ArticleId><ArticleId IdType="pubmed">29862846</ArticleId></ArticleIdList></Reference><Reference><Citation>Alshikho MJ, Zurcher NR, Loggia ML, et al. Integrated magnetic resonance imaging and [(11) C]-PBR28 positron emission tomographic imaging in amyotrophic lateral sclerosis. Ann Neurol. Jun 2018;83(6):1186&#x2013;1197. doi:10.1002/ana.25251</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.25251</ArticleId><ArticleId IdType="pmc">PMC6105567</ArticleId><ArticleId IdType="pubmed">29740862</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Weehaeghe D, Devrome M, Schramm G, et al. Combined brain and spinal FDG PET allows differentiation between ALS and ALS mimics. Eur J Nucl Med Mol Imaging. Oct 2020;47(11):2681&#x2013;2690. doi:10.1007/s00259-020-04786-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00259-020-04786-y</ArticleId><ArticleId IdType="pubmed">32314027</ArticleId></ArticleIdList></Reference><Reference><Citation>Nasseroleslami B, Dukic S, Broderick M, et al. Characteristic Increases in EEG Connectivity Correlate With Changes of Structural MRI in Amyotrophic Lateral Sclerosis. Cereb Cortex. Jan 1 2019;29(1):27&#x2013;41. doi:10.1093/cercor/bhx301</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cercor/bhx301</ArticleId><ArticleId IdType="pubmed">29136131</ArticleId></ArticleIdList></Reference><Reference><Citation>Dukic S, McMackin R, Buxo T, et al. Patterned functional network disruption in amyotrophic lateral sclerosis. Hum Brain Mapp. Nov 1 2019;40(16):4827&#x2013;4842. doi:10.1002/hbm.24740</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hbm.24740</ArticleId><ArticleId IdType="pmc">PMC6852475</ArticleId><ArticleId IdType="pubmed">31348605</ArticleId></ArticleIdList></Reference><Reference><Citation>Sorrentino P, Rucco R, Jacini F, et al. Brain functional networks become more connected as amyotrophic lateral sclerosis progresses: a source level magnetoencephalographic study. Neuroimage Clin. 2018;20:564&#x2013;571. doi:10.1016/j.nicl.2018.08.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nicl.2018.08.001</ArticleId><ArticleId IdType="pmc">PMC6120607</ArticleId><ArticleId IdType="pubmed">30186760</ArticleId></ArticleIdList></Reference><Reference><Citation>Vucic S, Pavey N, Haidar M, Turner BJ, Kiernan MC. Cortical hyperexcitability: Diagnostic and pathogenic biomarker of ALS. Neurosci Lett. Aug 10 2021;759:136039. doi:10.1016/j.neulet.2021.136039</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2021.136039</ArticleId><ArticleId IdType="pubmed">34118310</ArticleId></ArticleIdList></Reference><Reference><Citation>Swash M, Burke D, Turner MR, et al. Occasional essay: Upper motor neuron syndrome in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. Mar 2020;91(3):227&#x2013;234. doi:10.1136/jnnp-2019-321938</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2019-321938</ArticleId><ArticleId IdType="pubmed">32054724</ArticleId></ArticleIdList></Reference><Reference><Citation>Saba L, Viscomi MT, Caioli S, et al. Altered Functionality, Morphology, and Vesicular Glutamate Transporter Expression of Cortical Motor Neurons from a Presymptomatic Mouse Model of Amyotrophic Lateral Sclerosis. Cereb Cortex. Apr 2016;26(4):1512&#x2013;28. doi:10.1093/cercor/bhu317</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cercor/bhu317</ArticleId><ArticleId IdType="pubmed">25596588</ArticleId></ArticleIdList></Reference><Reference><Citation>Huynh W, Dharmadasa T, Vucic S, Kiernan MC. Functional Biomarkers for Amyotrophic Lateral Sclerosis. Front Neurol. 2018;9:1141. doi:10.3389/fneur.2018.01141</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2018.01141</ArticleId><ArticleId IdType="pmc">PMC6328463</ArticleId><ArticleId IdType="pubmed">30662429</ArticleId></ArticleIdList></Reference><Reference><Citation>Eisen A, Braak H, Del Tredici K, Lemon R, Ludolph AC, Kiernan MC. Cortical influences drive amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. Nov 2017;88(11):917&#x2013;924. doi:10.1136/jnnp-2017-315573</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2017-315573</ArticleId><ArticleId IdType="pubmed">28710326</ArticleId></ArticleIdList></Reference><Reference><Citation>Menon P, Geevasinga N, Yiannikas C, Howells J, Kiernan MC, Vucic S. Sensitivity and specificity of threshold tracking transcranial magnetic stimulation for diagnosis of amyotrophic lateral sclerosis: a prospective study. Lancet Neurol. May 2015;14(5):478&#x2013;84. doi:10.1016/s1474-4422(15)00014-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s1474-4422(15)00014-9</ArticleId><ArticleId IdType="pubmed">25843898</ArticleId></ArticleIdList></Reference><Reference><Citation>Geevasinga N, Menon P, Sue CM, et al. Cortical excitability changes distinguish the motor neuron disease phenotypes from hereditary spastic paraplegia. Eur J Neurol. May 2015;22(5):826&#x2013;31, e57&#x2013;8. doi:10.1111/ene.12669</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.12669</ArticleId><ArticleId IdType="pubmed">25683471</ArticleId></ArticleIdList></Reference><Reference><Citation>Menon P, Yiannikas C, Kiernan MC, Vucic S. Regional motor cortex dysfunction in amyotrophic lateral sclerosis. Ann Clin Transl Neurol. Aug 2019;6(8):1373&#x2013;1382. doi:10.1002/acn3.50819</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.50819</ArticleId><ArticleId IdType="pmc">PMC6689694</ArticleId><ArticleId IdType="pubmed">31402622</ArticleId></ArticleIdList></Reference><Reference><Citation>Dharmadasa T, Matamala JM, Howells J, Vucic S, Kiernan MC. Early focality and spread of cortical dysfunction in amyotrophic lateral sclerosis: A regional study across the motor cortices. Clin Neurophysiol. Apr 2020;131(4):958&#x2013;966. doi:10.1016/j.clinph.2019.11.057</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinph.2019.11.057</ArticleId><ArticleId IdType="pubmed">31959568</ArticleId></ArticleIdList></Reference><Reference><Citation>Agarwal S, Highton-Williamson E, Caga J, et al. Motor cortical excitability predicts cognitive phenotypes in amyotrophic lateral sclerosis. Sci Rep. Jan 26 2021;11(1):2172. doi:10.1038/s41598-021-81612-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-81612-x</ArticleId><ArticleId IdType="pmc">PMC7838179</ArticleId><ArticleId IdType="pubmed">33500476</ArticleId></ArticleIdList></Reference><Reference><Citation>Menon P, Higashihara M, van den Bos M, Geevasinga N, Kiernan MC, Vucic S. Cortical hyperexcitability evolves with disease progression in ALS. Ann Clin Transl Neurol. May 2020;7(5):733&#x2013;741. doi:10.1002/acn3.51039</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.51039</ArticleId><ArticleId IdType="pmc">PMC7261748</ArticleId><ArticleId IdType="pubmed">32304186</ArticleId></ArticleIdList></Reference><Reference><Citation>Dharmadasa T, Howells J, Matamala JM, et al. Cortical inexcitability defines an adverse clinical profile in amyotrophic lateral sclerosis. Eur J Neurol. Jan 2021;28(1):90&#x2013;97. doi:10.1111/ene.14515</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.14515</ArticleId><ArticleId IdType="pmc">PMC7820947</ArticleId><ArticleId IdType="pubmed">32902860</ArticleId></ArticleIdList></Reference><Reference><Citation>Wainger BJ, Macklin EA, Vucic S, et al. Effect of Ezogabine on Cortical and Spinal Motor Neuron Excitability in Amyotrophic Lateral Sclerosis: A Randomized Clinical Trial. JAMA Neurol. Feb 1 2021;78(2):186&#x2013;196. doi:10.1001/jamaneurol.2020.4300</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2020.4300</ArticleId><ArticleId IdType="pmc">PMC7684515</ArticleId><ArticleId IdType="pubmed">33226425</ArticleId></ArticleIdList></Reference><Reference><Citation>Grollemund V, Pradat PF, Querin G, et al. Machine Learning in Amyotrophic Lateral Sclerosis: Achievements, Pitfalls, and Future Directions. Front Neurosci. 2019;13:135. doi:10.3389/fnins.2019.00135</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2019.00135</ArticleId><ArticleId IdType="pmc">PMC6403867</ArticleId><ArticleId IdType="pubmed">30872992</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang M, Gao C, Goutman SA, et al. Model-Based and Model-Free Techniques for Amyotrophic Lateral Sclerosis Diagnostic Prediction and Patient Clustering. Neuroinformatics. Jul 2019;17(3):407&#x2013;421. doi:10.1007/s12021-018-9406-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12021-018-9406-9</ArticleId><ArticleId IdType="pmc">PMC6527505</ArticleId><ArticleId IdType="pubmed">30460455</ArticleId></ArticleIdList></Reference><Reference><Citation>Benatar M, Turner MR, Wuu J. Defining pre-symptomatic amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. Aug 2019;20(5&#x2013;6):303&#x2013;309. doi:10.1080/21678421.2019.1587634</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2019.1587634</ArticleId><ArticleId IdType="pmc">PMC6613999</ArticleId><ArticleId IdType="pubmed">30892087</ArticleId></ArticleIdList></Reference><Reference><Citation>Burke T, Pinto-Grau M, Lonergan K, et al. A Cross-sectional population-based investigation into behavioral change in amyotrophic lateral sclerosis: subphenotypes, staging, cognitive predictors, and survival. Ann Clin Transl Neurol. May 2017;4(5):305&#x2013;317. doi:10.1002/acn3.407</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.407</ArticleId><ArticleId IdType="pmc">PMC5420811</ArticleId><ArticleId IdType="pubmed">28491898</ArticleId></ArticleIdList></Reference><Reference><Citation>Elamin M, Pinto-Grau M, Burke T, et al. Identifying behavioural changes in ALS: Validation of the Beaumont Behavioural Inventory (BBI). Amyotroph Lateral Scler Frontotemporal Degener. Feb 2017;18(1&#x2013;2):68&#x2013;73. doi:10.1080/21678421.2016.1248976</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2016.1248976</ArticleId><ArticleId IdType="pubmed">27894191</ArticleId></ArticleIdList></Reference><Reference><Citation>Goutman SA, Chen KS, Paez-Colasante X, Feldman EL. Emerging understanding of the genotype-phenotype relationship in amyotrophic lateral sclerosis. Handb Clin Neurol. 2018;148:603&#x2013;623. doi:10.1016/b978-0-444-64076-5.00039-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/b978-0-444-64076-5.00039-9</ArticleId><ArticleId IdType="pubmed">29478603</ArticleId></ArticleIdList></Reference><Reference><Citation>Chia R, Chio A, Traynor BJ. Novel genes associated with amyotrophic lateral sclerosis: diagnostic and clinical implications. Lancet Neurol. Jan 2018;17(1):94&#x2013;102. doi:10.1016/s1474-4422(17)30401-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s1474-4422(17)30401-5</ArticleId><ArticleId IdType="pmc">PMC5901717</ArticleId><ArticleId IdType="pubmed">29154141</ArticleId></ArticleIdList></Reference><Reference><Citation>Marin B, Boumediene F, Logroscino G, et al. Variation in worldwide incidence of amyotrophic lateral sclerosis: a meta-analysis. Int J Epidemiol. Feb 1 2017;46(1):57&#x2013;74. doi:10.1093/ije/dyw061</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ije/dyw061</ArticleId><ArticleId IdType="pmc">PMC5407171</ArticleId><ArticleId IdType="pubmed">27185810</ArticleId></ArticleIdList></Reference><Reference><Citation>Chio A, Logroscino G, Traynor BJ, et al. Global epidemiology of amyotrophic lateral sclerosis: a systematic review of the published literature. Neuroepidemiology. 2013;41(2):118&#x2013;30. doi:10.1159/000351153</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000351153</ArticleId><ArticleId IdType="pmc">PMC4049265</ArticleId><ArticleId IdType="pubmed">23860588</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta P, Kaye W, Raymond J, et al. Prevalence of Amyotrophic Lateral Sclerosis - United States, 2015. MMWR Morb Mortal Wkly Rep. Nov 23 2018;67(46):1285&#x2013;1289. doi:10.15585/mmwr.mm6746a1</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm6746a1</ArticleId><ArticleId IdType="pmc">PMC6289079</ArticleId><ArticleId IdType="pubmed">30462626</ArticleId></ArticleIdList></Reference><Reference><Citation>Arthur KC, Calvo A, Price TR, Geiger JT, Chio A, Traynor BJ. Projected increase in amyotrophic lateral sclerosis from 2015 to 2040. Nat Commun. Aug 11 2016;7:12408. doi:10.1038/ncomms12408</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms12408</ArticleId><ArticleId IdType="pmc">PMC4987527</ArticleId><ArticleId IdType="pubmed">27510634</ArticleId></ArticleIdList></Reference><Reference><Citation>Manjaly ZR, Scott KM, Abhinav K, et al. The sex ratio in amyotrophic lateral sclerosis: A population based study. Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases. Oct 2010;11(5):439&#x2013;42. doi:10.3109/17482961003610853</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482961003610853</ArticleId><ArticleId IdType="pmc">PMC6485484</ArticleId><ArticleId IdType="pubmed">20225930</ArticleId></ArticleIdList></Reference><Reference><Citation>de Carvalho M, Kiernan MC, Swash M. Fasciculation in amyotrophic lateral sclerosis: origin and pathophysiological relevance. J Neurol Neurosurg Psychiatry. Sep 2017;88(9):773&#x2013;779. doi:10.1136/jnnp-2017-315574</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2017-315574</ArticleId><ArticleId IdType="pubmed">28490504</ArticleId></ArticleIdList></Reference><Reference><Citation>Vucic S, Rutkove SB. Neurophysiological biomarkers in amyotrophic lateral sclerosis. Curr Opin Neurol. Oct 2018;31(5):640&#x2013;647. doi:10.1097/wco.0000000000000593</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/wco.0000000000000593</ArticleId><ArticleId IdType="pubmed">30080715</ArticleId></ArticleIdList></Reference><Reference><Citation>Verde F, Silani V, Otto M. Neurochemical biomarkers in amyotrophic lateral sclerosis. Curr Opin Neurol. Oct 2019;32(5):747&#x2013;757. doi:10.1097/wco.0000000000000744</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/wco.0000000000000744</ArticleId><ArticleId IdType="pubmed">31403480</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi SJ, Hong YH, Kim SM, Shin JY, Suh YJ, Sung JJ. High neutrophil-to-lymphocyte ratio predicts short survival duration in amyotrophic lateral sclerosis. Sci Rep. Jan 16 2020;10(1):428. doi:10.1038/s41598-019-57366-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-019-57366-y</ArticleId><ArticleId IdType="pmc">PMC6965090</ArticleId><ArticleId IdType="pubmed">31949271</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>